



Mankind

Serving Life

May 8, 2025

BSE Limited

P J Towers,
Dalal Street,
Mumbai – 400 001

National Stock Exchange of India Limited

Exchange Plaza, C-1, Block G,
Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051

Scrip Code: 543904

Symbol: MANKIND

Dear Sir/ Madam,

Subject: Intimation of Board Meeting under Regulation 29 and 50 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Pursuant to Regulation 29 and 50 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that a meeting of Board of Directors of the Company is scheduled to be held on Wednesday, May 21, 2025, inter-alia to consider and approve the standalone and consolidated audited financial results of the Company for the quarter and financial year ended on March 31, 2025.

Further, in continuation of our earlier letter dated March 26, 2025 under subject 'Closure of Trading Window under SEBI (Prohibition of Insider Trading) Regulations, 2015 and the Company's 'Code of Conduct for Prevention of Insider Trading', the trading window for trading in the securities of the Company shall remain closed till May 23, 2025

You are requested to kindly take the above information on your records.

Thanking You,

Yours Faithfully,

For **Mankind Pharma Limited**

Hitesh Kumar Jain

Company Secretary and Compliance Officer

MANKIND PHARMA LIMITED

Regd. Office : 208, Okhla Ind. Estate, Phase - 3, New Delhi-110020 • Ph. : 011-46846700, 47476600
CIN No. L74899DL1991 PLC044843 • E-mail : contact@mankindpharma.com • www.mankindpharma.com